In honor of world #rarediseaseday, we are raising awareness of #BKV associated diseases that are devastating to transplant. At Amplyx, we are proud to be working on treatments for these patients who have unmet medical needs. #RDD2020

It’s not just #coronavirus. “If there’s one infectious disease issue that we need to worry about, it’s #antibioticresistance.” Join the fight with #WTFAMR. montrealgazette.com/opinion/column…

This is pretty sobering. The "they" is oncologists: "Ninety-five percent said they worry about the impact of superbugs on the future of cancer treatments. Nearly half of those surveyed—46 percent—said they think chemotherapy will soon be unviable." ow.ly/6Rqw50yK4VG

During the 2009 H1N1 pandemic, 29% of people with fatal pandemic #influenza were found to have bacterial co-infections. The development and use of novel #antimicrobials is critical to our ability to save lives during a global pandemic.

Continued development of innovative antimicrobials is critical, now more than ever. Lack of effective therapies increase the need for ventilators and increase mortality. Keep DISARM in #COVID relief bill future needs @GOPLeader Nancy Pelosi Antimicrobials Working Group Scott Gottlieb, MD 🇺🇸

COVID-19 and ASPERGILLUS: Invasive pulmonary aspergillosis is a known complication of severe influenza, and discussions are emerging now on potential co-infection with COVID-19. MRC Centre for Medical Mycology is summarizing the current knowledge at exeter.ac.uk/medicalmycolog… #covidANDaspergillosis

Our annual update on #antibiotics in clinical development is here. Right now, there are too few antibiotics in development—but more are needed. Full findings: pew.org/2K8McAQ

The US needs to be equipped to combat ongoing and future public health emergencies, such as superbugs. You can help make a difference: #COVID19 pew.org/2VeDaqV

.Amplyx, now a subsidiary of Pfizer Inc., Cidara Therapeutics, and @SCYNEXIS will participate in panel discussions as part of Maxim Group's Infectious Disease Virtual Conference, highlighting innovation in the #InfectiousDisease sector and need for new anti-infectives to combat #AMR. RSVP bit.ly/3eUHogy

.Amplyx, now a subsidiary of Pfizer Inc. to Participate in Antifungal Panel at Maxim Group's Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector bit.ly/2WelwnW

Emerging reports suggest as many as 1/3 of patients with severe COVID-19 infection may also be battling invasive aspergillosis, a deadly fungal superinfection caused by Aspergillus mold, says Amplyx, now a subsidiary of Pfizer Inc. CEO Ciara Kennedy xconomy.com/san-diego/2020…

COVID-19 and fungal superinfections could lead to a deadly, perfect storm. Read more from Ciara Kennedy, Ph.D., President & CEO, Amplyx in Xconomy xconomy.com/san-diego/2020…

We announced the closure of a Series C financing to advance clinical development of our novel product candidates for the treatment of life-threatening diseases affecting patients with compromised immune systems. Learn more: amplyx.com/amplyx-pharmac…

We're pleased to announce positive top-line data following the completion of our Phase 2 clinical trial of #Fosmanogepix, a novel antifungal therapy in development for patients with invasive fungal infections. Learn more: amplyx.com/amplyx-announc…

.Endpoints News shares positive topline data from Amplyx, now a subsidiary of Pfizer Inc.'s Phase 2 trial of fosmangepix, an antifungal with the potential to treat patients with life-threatening #Candida infections. The Phase 3 trial is likely to commence in 2021. Learn more: bit.ly/2CX42pV

bioworld.com/articles/49833…

AWG has appointed Ciara Kennedy, President and CEO of Amplyx, now a subsidiary of Pfizer Inc. as the new Chair of AWG. Dr. Kennedy replaces Evan Loh, CEO of Paratek, who has completed his two-year term as Chairman. bit.ly/2MyRutF

Incoming AWG Chair, Ciara Kennedy, President and CEO of Amplyx, now a subsidiary of Pfizer Inc., highlights the coalitions priorities in 2021 and beyond:

Today is #WorldAspergillosisDay. Invasive aspergillosis and mucormycosis are serious mould infections – don’t forget to #ThinkFungus At Amplyx, we are proud to be developing a first-in-class antifungal with the potential to treat these life-threatening infections.

On Thursday, March 25 at 11 am ET, our CEO, Ciara Kennedy, will participate in a live discussion with industry experts about the critical healthcare burden associated with #sepsis. A live Q&A will follow. Learn more: